CTLT Logo

Catalent, Inc. (CTLT) 

NYSE
Market Cap
$10.89B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
512 of 776
Rank in Industry
26 of 47

Largest Insider Buys in Sector

CTLT Stock Price History Chart

CTLT Stock Performance

About Catalent, Inc.

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary …

Insider Activity of Catalent, Inc.

Over the last 12 months, insiders at Catalent, Inc. have bought $0 and sold $1.4M worth of Catalent, Inc. stock.

On average, over the past 5 years, insiders at Catalent, Inc. have bought $671,930 and sold $328.16M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,000 shares for transaction amount of $49,980 was made by Ryan Michelle R (director) on 2023‑08‑31.

List of Insider Buy and Sell Transactions, Catalent, Inc.

2024-10-18SaleSVP, General Counsel, CCO
320
0.0002%
$59.97$19,190-2.62%
2024-09-26SaleGroup President, Biologics
1,994
0.0011%
$59.97$119,580+0.53%
2024-08-02SaleGroup Pres. Pharma & Consumer
1,169
0.0006%
$59.55$69,614+0.77%
2024-08-02SaleSVP, Quality & Reg. Affairs
666
0.0004%
$59.55$39,660+0.77%
2024-08-02SaleSVP, Chief HR Officer
3,859
0.0021%
$59.67$230,267+0.77%
2024-08-02SalePres. BioProduct Delivery, CoS
662
0.0004%
$59.56$39,429+0.77%
2024-08-02SaleSVP, General Counsel, CCO
608
0.0003%
$59.58$36,225+0.77%
2024-07-29SalePresident & CEO
9,088
0.005%
$58.76$534,011+1.74%
2024-07-29SaleGroup Pres. Pharma & Consumer
349
0.0002%
$58.70$20,486+1.74%
2024-07-29SaleSVP, Quality & Reg. Affairs
283
0.0002%
$58.69$16,609+1.74%
2024-07-29SalePres. BioProduct Delivery, CoS
206
0.0001%
$58.67$12,086+1.74%
2024-07-08SaleSVP, Chief Financial Officer
2,993
0.0017%
$56.74$169,8230.00%
2024-06-04SalePres. BioProduct Delivery, CoS
1,401
0.0008%
$54.26$76,023+8.44%
2024-03-15SaleSVP, Quality & Reg. Affairs
387
0.0002%
$56.20$21,749+0.95%
2023-08-31Purchasedirector
1,000
0.0006%
$49.98$49,980+9.95%
2023-08-30PurchaseExecutive Chair
21,000
0.012%
$50.24$1.06M+12.17%
2023-08-24SaleGroup Pres. Pharma & Consumer
396
0.0002%
$44.49$17,618+22.22%
2023-08-24SalePresident & CEO
2,071
0.0011%
$44.54$92,245+22.22%
2023-08-24SaleEVP & Chief Admin Officer
817
0.0004%
$44.65$36,479+22.22%
2023-08-24SaleSVP, CCO & Div. Head BioP Del.
87
<0.0001%
$44.87$3,904+22.22%

Insider Historical Profitability

17.86%
MOREL DONALD E JRdirector
46958
0.0259%
$60.0030+15.26%
BUZY PETER LPresident, Gene Therapy
44500
0.0245%
$60.0010+17.25%
GREISCH JOHN JExecutive Chair
34000
0.0187%
$60.0020+20.08%
Roehrhoff Uwedirector
16489
0.0091%
$60.0010+6.41%
Ryan Michelle Rdirector
1979
0.0011%
$60.0010

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$1.15B11.2820.41M+1.08%+$12.34M0.02
BlackRock$857.85M8.415.2M-6.05%-$55.29M0.02
Capital World Investors$729.58M7.1412.92M-32.26%-$347.48M0.12
Nomura Holdings$635.69M6.2211.26M-1.97%-$12.77M5.55
Janus Henderson$539.7M5.289.56M-27.84%-$208.22M0.27
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.